CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
Yi‐Hung Carol Tan(National Taiwan Normal University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 105
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
|Cancer Research|2007|260
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
|Clinical Cancer Research|2007|154